Protein Phosphatase 1H, Cyclin-Dependent Kinase Inhibitor p27, and Cyclin-Dependent Kinase 2 in Paclitaxel Resistance for Triple Negative Breast Cancers.
Cyclin-dependent kinase 2
Cyclin-dependent kinase inhibitor p27
PPM1H protein
Paclitaxel
Journal
Journal of breast cancer
ISSN: 1738-6756
Titre abrégé: J Breast Cancer
Pays: Korea (South)
ID NLM: 101314183
Informations de publication
Date de publication:
04 2020
04 2020
Historique:
received:
24
10
2019
accepted:
26
02
2020
entrez:
13
5
2020
pubmed:
13
5
2020
medline:
13
5
2020
Statut:
ppublish
Résumé
Paclitaxel is a cytotoxic chemotherapy commonly used in patients with triple negative breast cancer (TNBC); however, the resistance to paclitaxel is a cause of poor response in the patients. The aim of this study was to examine the role of protein phosphatase 1H (PPM1H) in paclitaxel resistance in breast cancer patients. To investigate the function of PPM1H in paclitaxel treatment, we conducted We investigated whether PPM1H was associated with paclitaxel resistance in breast cancer. PPM1H expression was upregulated in breast cancer cells treated with paclitaxel. We also observed that overexpression of PPM1H in breast cancer cells resulted in increased sensitivity to paclitaxel CDK2 kinase activity was significantly upregulated in basal breast cancer tumors and was negatively correlated with p27 protein levels in the TCGA breast cancer dataset, suggesting that targeting CDK2 may be an effective treatment strategy for TNBC patients.
Identifiants
pubmed: 32395375
doi: 10.4048/jbc.2020.23.e20
pmc: PMC7192749
doi:
Types de publication
Journal Article
Langues
eng
Pagination
162-170Informations de copyright
© 2020 Korean Breast Cancer Society.
Déclaration de conflit d'intérêts
Conflict of Interest: The authors declare that they have no competing interests.
Références
Cancer Epidemiol Biomarkers Prev. 2016 Jan;25(1):16-27
pubmed: 26667886
Cancer Discov. 2011 Sep;1(4):326-37
pubmed: 22586611
J Exp Med. 2012 Apr 9;209(4):679-96
pubmed: 22430491
Nat Rev Cancer. 2013 Oct;13(10):714-26
pubmed: 24060863
Clin Cancer Res. 2017 Sep 15;23(18):5561-5572
pubmed: 28606920
Curr Biol. 1999 Jun 17;9(12):661-4
pubmed: 10375532
Nature. 2012 Apr 18;486(7403):346-52
pubmed: 22522925
Science. 1995 Aug 4;269(5224):682-5
pubmed: 7624798
Breast Cancer Res. 2009;11(5):R77
pubmed: 19874578
Lancet Oncol. 2015 Jan;16(1):25-35
pubmed: 25524798
Lancet Oncol. 2018 Jan;19(1):27-39
pubmed: 29242041
Nat Methods. 2007 Apr;4(4):359-65
pubmed: 17396127
Lancet Oncol. 2016 Apr;17(4):425-439
pubmed: 26947331
N Engl J Med. 2016 Nov 17;375(20):1925-1936
pubmed: 27959613
Oncogene. 2017 May 4;36(18):2491-2502
pubmed: 27819669
Ann Oncol. 2012 Mar;23(3):547-55
pubmed: 21896541
Cancer Treat Rev. 2012 Nov;38(7):890-903
pubmed: 22465195
Eur J Cancer. 2004 Apr;40(6):802-20
pubmed: 15120036
Drug Discov Today. 2013 Mar;18(5-6):240-9
pubmed: 23073387